MedTrace Logo

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

NCT02753400 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-05-19

Study results available
· View outcomes & findings →

Summary

To evaluate the effects of oral emixustat hydrochloride (emixustat) on aqueous humor biomarkers associated with proliferative diabetic retinopathy (PDR) from baseline to week 12.

Conditions

  • Proliferative Diabetic Retinopathy

Interventions

DRUG

emixustat hydrochloride

Tablet for oral administration

OTHER

Placebo

Placebo tablets for oral administration contain only inactive ingredients

Sponsors & Collaborators

  • Kubota Vision Inc.

    lead INDUSTRY

Principal Investigators

  • Responsible Medical Officer · Kubota Vision Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-11-30
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02753400 on ClinicalTrials.gov